What is the appropriate dose of ursodeoxycholic acid (Ursofalk) for a 20‑kg patient with cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ursofalk Dosing for 20 kg Patient with Cirrhosis

For a 20 kg patient with cirrhosis (specifically primary biliary cholangitis/PBC), administer Ursofalk at 13-15 mg/kg/day, which equals 260-300 mg daily, given as a single daily dose or divided doses.

Recommended Dose Calculation

The most recent AASLD/AGA guideline from 2026 explicitly recommends 13-15 mg/kg/day as first-line therapy for all patients with PBC 1. This is consistent across both guideline and research evidence.

For your 20 kg patient:

  • Minimum dose: 13 mg/kg × 20 kg = 260 mg/day
  • Maximum dose: 15 mg/kg × 20 kg = 300 mg/day

Evidence Supporting This Dosing

The 2026 AASLD/AGA guideline provides the strongest recommendation, stating that UDCA 13-15 mg/kg/day should be initiated as first-line therapy for all patients with PBC 1. This dosing range is supported by multiple high-quality studies:

  • A 1999 dose-response study in early-stage PBC found that 900 mg/day (equivalent to 13.5 mg/kg/day) was the optimum dose, producing the greatest enrichment of UDCA in serum bile acids and the best normalization of liver function tests 2

  • Research from 2018 emphasizes that 13-15 mg/kg/day is the correct dosage determined by body weight, and notes that a significant number of UK patients are being underdosed, with over one-third of partial responders becoming responders within 2 years after increasing to recommended levels 3

  • Multiple studies confirm this range improves biochemical markers and may delay disease progression 4, 5, 6

Critical Dosing Pitfalls to Avoid

Underdosing is a common and serious error. The FDA label mentions that doses of 8-10 mg/kg/day were used for gallstone dissolution 7, but this is insufficient for PBC treatment. Research shows that approximately one-third of patients initially classified as partial responders become full responders simply by increasing the dose to the recommended 13-15 mg/kg/day range 3.

Lower doses (300-600 mg/day in adults) have been shown to be significantly less effective than 900-1200 mg/day doses for normalizing liver enzymes 2.

Monitoring and Response Assessment

  • Monitor liver enzymes every 3 months for the first year 1
  • Assess response at 12 months: adequate response is defined as achieving serum alkaline phosphatase levels <1.5-1.67 times the upper limit of normal and normal total bilirubin 1
  • Consider measuring liver stiffness (≥10 kPa by VCTE indicates high-risk for unfavorable outcomes) 1
  • If high-risk features are present, assess response at 6 months 1

Context for Cirrhosis

While the evidence primarily addresses PBC (which progresses to biliary cirrhosis), the dosing remains 13-15 mg/kg/day regardless of disease stage. Studies included patients with varying stages of disease, from early-stage to advanced cirrhosis (15-83% with advanced disease), and the same dosing was effective across the spectrum 4, 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.